GoodRx aims to provide the highest level of quality research about drugs, their availability and their cost. To fulfill this aim, the company supplements the data generated internally with data from external sources. The GoodRx Research team leverages these sources to track drug utilization, drug pricing, and drug shortages, and inform patients that may be impacted. Some of these sources are in the public domain, provided by the government generally, while other data sources are licensed. This document describes the coverage of licensed data and potential use to describe drug trends and utilization patterns in the United States.
GoodRx uses a representative sample of de-identified pharmacy claims across the United States, representing a wide range of channels and providers. Data includes the drug and quantity that was dispensed, the location and date of the transaction, and the usual and customary cost (U&C) of the product that was dispensed. The U&C cost is what would be paid by the patient in the absence of a contracted rate, or insurance price.
These data do not include any personal identifiers, and do not include information on what was paid for the medication.
The GoodRx Research team combines these claims with information on drugs from the GoodRx proprietary drug database and data on pharmacies to analyze trends in utilization and variation across geographic locales for specific drugs, classes of drugs, and medical conditions for which different drugs are prescribed.
Read the full report here.
Co-contributors: Diane Li, Tori Marsh, MPH, and Amanda Nguyen, PhD
Why trust our experts?
